Signal Advisors Wealth LLC Buys 4,464 Shares of Novo Nordisk A/S (NYSE:NVO)

Signal Advisors Wealth LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 39.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,874 shares of the company’s stock after acquiring an additional 4,464 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Novo Nordisk A/S were worth $1,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. AAFMAA Wealth Management & Trust LLC grew its position in Novo Nordisk A/S by 35.2% in the 4th quarter. AAFMAA Wealth Management & Trust LLC now owns 17,357 shares of the company’s stock worth $1,493,000 after purchasing an additional 4,519 shares in the last quarter. Tealwood Asset Management Inc. grew its holdings in shares of Novo Nordisk A/S by 1.6% in the fourth quarter. Tealwood Asset Management Inc. now owns 14,336 shares of the company’s stock valued at $1,233,000 after acquiring an additional 220 shares in the last quarter. AdvisorNet Financial Inc increased its position in shares of Novo Nordisk A/S by 24.8% during the fourth quarter. AdvisorNet Financial Inc now owns 2,791 shares of the company’s stock valued at $240,000 after acquiring an additional 554 shares during the last quarter. PFW Advisors LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth $329,000. Finally, Burns J W & Co. Inc. NY boosted its position in Novo Nordisk A/S by 3.2% in the fourth quarter. Burns J W & Co. Inc. NY now owns 5,605 shares of the company’s stock worth $482,000 after purchasing an additional 175 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $84.43 on Tuesday. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The firm’s fifty day moving average price is $99.84 and its 200-day moving average price is $118.61. The stock has a market cap of $378.88 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Ratings Changes

Several brokerages have recently issued reports on NVO. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.